Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503775 | 1.00 | KMT2A (0.54) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29362505 | 1.00 | KMT2A (0.54) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL6673476 | 0.89 | KMT2A (0.54) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL30809552 | 0.88 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL18557550 | 0.88 | KMT2A (0.56) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL11947976 | 0.88 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL6647665 | 0.88 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL15434691 | 0.88 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL10205819 | 0.87 | KMT2A (0.58) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL12560390 | 0.86 | KMT2A (0.52) | KMT2AEPHX2CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102443048-A | Synthetic method of 5-membered cyclopeptide | JIANGSU YEW PHARMACEUTICAL CO LTD | 2012-05-09 | — | — | CN | claimed |
| US-5385910-A | Gem-distributed esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-1089964-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| CN-1427838-A | Hydantoin-containing glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-07-02 | — | — | CN | disclosed |
| US-6583288-B2 | (S,S)-2-((2-(4-(cyclohexyl)methyl-2,5-dioxoimidazolidin-1-yl)-3 -cyclopentylpropanoyl) amino)thiazole-4-carboxylic acid, methyl ester for example; for treatment of diabetes | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| US-20010056191-A1 | Hydantoin-containing glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
| US-6239151-B1 | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, OSTEOARTHRITIS, RESPIRATORY DISEASES, TUMORS, CACHEXIA, CARDIOVASCULAR DISEASES, FEVER, HAEMORRHAGE AND SEPSIS, HYDRAZINE DERIVATIVES, | HOFFMANN-LA ROCHE INC. | 2001-05-29 | — | — | US | disclosed |
| EP-1089964-A1 | HYDRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000465-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-06 | — | — | WO | disclosed |
| US-5385910-A | Gem-distributed esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885EPHX2 4299/4885CASP3 795/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KMT2A 2834/4885EPHX2 579/4885CASP3 53/4885 |
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | NGLY1, VIP, DNPEP | KMT2A 4624/4885EPHX2 2578/4885CASP3 336/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885EPHX2 3153/4885CASP3 2833/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885EPHX2 3153/4885CASP3 2833/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | KMT2A 3145/4885EPHX2 3594/4885CASP3 3906/4885 |
| US-20010056191-A1 | Hydantoin-containing glucokinase activators | GCK, GCKR, HK2 | KMT2A 2369/4885EPHX2 2702/4885CASP3 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.